
Opinion|Videos|April 17, 2024
Social Burden and Goals of Therapy for Patients with Bronchiectasis
A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.
Advertisement
Episodes in this series

Advertisement
Related to this article

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
3
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
4
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
5



